Best Alternatives to GLP-1 Medications: What Else Works [2026]

Last updated: April 2026

Medical Disclaimer: Informational only. Talk to your clinician before starting or stopping any medication. Individual results vary.

Affiliate Disclosure: Some links are affiliate links. We may earn a commission at no extra cost to you.

Alternatives at a Glance

Option	Mechanism	Expected Weight Loss	Monthly Cost	Best For	Verdict
Retatrutide (Phase 3)	Triple GLP-1/GIP/glucagon	-17-24%	TBD (2027)	Awaits FDA approval	Pipeline leader
Eloralintide (Phase 3)	Amylin agonist	-15-20%	TBD	GLP-1 non-responders	Best for non-responders
Contrave	Naltrexone + bupropion	-5-8%	$99-$300	Craving-driven eating	Modest but real
Qsymia	Phentermine + topiramate	-8-10%	$150-$250	Most effective non-GLP-1	Highest non-GLP-1 efficacy
Orlistat	Lipase inhibitor	-3-5%	$50-$80 OTC	Mild cases, OTC option	Lowest cost OTC
Metformin (off-label)	Insulin sensitizer	-2-5%	$4-$15	Insulin resistance, PCOS	Cheapest, well-tolerated
Bariatric surgery	Anatomical	-25-35%	$15K-$30K	BMI 40+ or 35+ with comorbidity	Most durable

Sources: SURMOUNT-OASIS Phase 3 (2025), FDA Drug Label Database (2026), Phase 3 trial readouts.

Why People Look for GLP-1 Alternatives

GLP-1 drugs have reshaped weight care. Wegovy and Zepbound hit 15-22% weight loss in trials. The full picture is messier than the headlines say.

Cost Remains the Biggest Barrier

Brand-name GLP-1s run $800-$1,300 a month without insurance. Even with generic semaglutide in 2026, supply and denials leave many out. The cash math just does not work.

A 2025 KFF survey found 4 in 10 adults who wanted to try a GLP-1 cited cost as the main reason they had not. Cash-pay programs help. They do not close the gap for everyone.

Tolerability Issues Stop Many Patients

Gastrointestinal side effects affect 40-70% of GLP-1 users — usually mild and transient, but for some patients they never fully resolve. Around 5-10% of participants in major trials discontinued treatment due to adverse effects per the STEP trial program (NEJM 2021-2025).

Non-Response Gets Less Attention Than It Should

Research shows that up to 17% of GLP-1 users are "non-responders." They lose little weight even on full doses. For them, a different drug class makes more sense.

Medical Contraindications Rule Out Some Patients

Patients with a family history of medullary thyroid cancer should avoid GLP-1s. So should those with MEN2 syndrome or severe gastroparesis. Pregnant or nursing women must not take these drugs per FDA labeling (2026).

Next-Generation Drugs Beyond Traditional GLP-1s

The pharmaceutical pipeline is stacked with next-generation candidates. These represent an evolution from first-generation options like Ozempic and Wegovy.

Retatrutide: The Triple Agonist

Retatrutide is the most talked-about drug in the pipeline. Lilly made it, and it hits three receptors at once: GLP-1, GIP, and glucagon. The glucagon piece boosts energy burn on top of cutting appetite.

Phase 2 trial results published in NEJM (2024) were striking. Participants on the highest dose achieved up to 24.2% body weight reduction after 48 weeks.

Phase 3 trials are underway. FDA approval potentially arrives in late 2026 or 2027 per Lilly's investor disclosures (2026). If the data holds up, retatrutide could become the most effective obesity medication ever approved.

Orforglipron: The Oral GLP-1

Orforglipron is also from Lilly. It is a small-molecule pill, not a peptide. Unlike Rybelsus, it is absorbed reliably with no meal timing rules.

In late-stage trials, participants lost an average of about 12% of body weight over 72 weeks. The catch: around 59% reported GI side effects compared with 37-45% on semaglutide.

An effective oral option could be transformative for patients who avoid GLP-1s specifically because of needle aversion.

Eloralintide: Targeting Amylin Instead

Eloralintide takes a different path. It is an amylin agonist, not a GLP-1 drug.

Amylin is a hormone co-released with insulin by beta cells. It cues satiety and slows the gut, like GLP-1 but on a different track.

In trials, patients lost up to 20% of body weight. Those who do not respond to GLP-1s may respond here.

MariTide (Maridebart Cafraglutide)

Amgen built MariTide. It turns GLP-1 on while blocking GIP — the reverse of tirzepatide. The idea is that blocking GIP cuts nausea.

Early data looks good. Monthly dosing beats weekly shots on convenience.

FDA-Approved Non-GLP-1 Weight Loss Medications

You do not need to wait for pipeline drugs. Several FDA-approved medications work through entirely different mechanisms. None deliver the same magnitude of weight loss as GLP-1s.

Contrave (Naltrexone/Bupropion)

Contrave combines naltrexone (an opioid blocker) with bupropion (an antidepressant that also cuts appetite). Together they target reward and hunger pathways at once.

In the COR clinical trial program, participants lost an average of 5-8% of body weight over 56 weeks. That is modest compared to GLP-1s but clinically meaningful.

Contrave is particularly useful for patients whose overeating is driven by cravings. Cost runs approximately $99-$300 per month.

Qsymia (Phentermine/Topiramate ER)

Qsymia pairs phentermine (appetite suppressant) with extended-release topiramate (an anti-seizure drug that boosts satiety). Together they are the most effective non-GLP-1 weight drug.

The CONQUER trial (Lancet 2011, follow-up 2024) showed average weight loss of 7.8% at mid dose and 9.8% at top dose over 56 weeks.

The downside: phentermine carries cardiovascular risks, and topiramate is teratogenic. Qsymia requires enrollment in a REMS program. Cost runs $150-$250 a month.

Orlistat (Xenical/Alli)

Orlistat works by inhibiting pancreatic lipase. It blocks absorption of about 30% of dietary fat. It is the only FDA-approved weight loss medication available over the counter.

Average weight loss is modest — about 3-5% of body weight in clinical trials. The main deterrent is side effects: oily stools, fecal urgency, and flatulence.

Cost runs about $50-$80 per month for OTC Alli. Prescription Xenical is $200+.

Metformin (Off-Label)

Metformin is not FDA-approved for weight loss but is widely used off-label. It is a diabetes drug. It cuts body weight by 2-5%.

It is cheap, with GoodRx prices starting at $4 a month. It is well-tolerated, with decades of safety data behind it. For PCOS or insulin resistance, metformin fixes a metabolic driver that diet alone may not touch.

Bariatric Surgery: The Most Durable Weight Loss Tool

For BMI 40+ or 35+ with comorbidities, bariatric surgery is still the most effective long-term tool. Common procedures include sleeve gastrectomy and gastric bypass. The newer SADI bypass is also in use.

Average weight loss is 25-35% of body weight, sustained at 10+ years per the STAMPEDE trial 10-year follow-up (NEJM 2024). That is the most durable weight loss any obesity intervention produces.

Surgery is invasive and irreversible in some cases. It carries surgical risks, and costs run $15,000-$30,000 out of pocket. Insurance coverage is common for qualified patients.

Natural and Lifestyle Approaches

The "natural" route gets dismissed too quickly in the GLP-1 era. Lifestyle changes alone produce 3-5% weight loss on average. That is real, sustainable, and free of pharmaceutical side effects.

High-Protein, Lower-Carb Eating

The most consistent finding in nutrition research is that higher protein helps. Aim for 1.0-1.6 g/kg per day to boost satiety and save lean mass while losing weight. A 2024 American Journal of Clinical Nutrition meta-analysis found higher-protein diets produced 1.2-2.4 kg more weight loss than standard-protein diets.

Mediterranean eating beats low-fat diets on weight and lipids. The PREDIMED trial proved the long-term benefit.

Resistance Training Plus Cardio

Resistance training saves lean mass during weight loss. Cardio creates the deficit. Together they beat either alone.

The 2026 ACSM consensus statement calls for 150+ minutes of moderate cardio and 2-3 resistance sessions per week. That same plan also boosts outcomes on GLP-1 therapy.

Berberine and Other Supplements

Berberine is the supplement that gets the most attention. It modestly reduces blood glucose and may produce 2-3 kg of weight loss over 12 weeks in trials. The "natural Ozempic" label is overhyped — efficacy is closer to metformin than to semaglutide.

Green tea extract, glucomannan, and acacia fiber have small but real effects on satiety and weight. None approach pharmaceutical-grade results.

Frequently Asked Questions

What is the closest natural alternative to Ozempic?

There is no natural compound that matches semaglutide's efficacy. Berberine produces 2-3 kg of weight loss over 12 weeks in trials per a 2024 systematic review, well below the 15% body weight loss seen with semaglutide. The closest mechanism mimics come from high-protein diets that improve endogenous GLP-1 secretion modestly. Realistic natural approaches deliver 3-5% weight loss compared to 15-22% on GLP-1s. Setting expectations matters.

Are there cheaper FDA-approved alternatives to GLP-1s?

Yes. Metformin off-label runs $4-$15 a month. Orlistat OTC runs $50-$80. Contrave runs $99-$300, and Qsymia runs $150-$250. None match GLP-1 efficacy, but for patients without insurance coverage, they are legitimate options. Generic semaglutide launching mid-to-late 2026 may close the gap further, with projected cash prices near $150 a month per ANDA filings from Teva, Mylan, and Aurobindo.

What works for GLP-1 non-responders?

About 17% of GLP-1 users do not achieve meaningful weight loss despite proper dosing. The most promising option for non-responders is amylin-based therapy. Eloralintide showed up to 20% weight loss in Phase 3 trials and works through a different receptor system. Patients who do not respond to GLP-1s may respond to amylin agonists. Outside pharmacology, bariatric surgery remains the most effective intervention for severe obesity, with 25-35% sustained loss at 10 years per STAMPEDE follow-up.

Is retatrutide better than Ozempic or Zepbound?

The Phase 2 data suggests yes. Retatrutide produced 24.2% body weight loss at 48 weeks in the highest dose group, exceeding the 20-22% seen with tirzepatide in SURMOUNT-1 and the 15% seen with semaglutide in STEP-1. Phase 3 trials are ongoing with potential FDA approval in late 2026 or 2027. The triple-agonist mechanism (GLP-1 + GIP + glucagon) appears to add metabolic benefits beyond appetite suppression.

Can I switch from a GLP-1 to a non-GLP-1 alternative?

Yes, with medical supervision. Tapering off a GLP-1 should be gradual to minimize rebound. Switching directly to Contrave or Qsymia is reasonable for patients who tolerated the GLP-1 but had insurance issues, while metformin works as a long-term adjunct. The Obesity Medicine Association 2026 practice statement recommends transition planning at least 4 weeks before discontinuing any GLP-1. Most patients regain weight after stopping unless an alternative intervention is in place. See our GLP-1 cycling vs continuous use guide.

The Bottom Line

GLP-1 medications are the most effective pharmacological weight loss tool available in 2026. They are not the only option, and they are not right for everyone.

For patients priced out, intolerant, or non-responsive, alternatives exist. Pipeline drugs like retatrutide and eloralintide will expand the toolkit further by 2027. FDA-approved non-GLP-1 medications deliver modest but real results today. Lifestyle changes — high protein, resistance training, Mediterranean eating — work for the patient willing to commit to them.

The best alternative depends on your specific situation. Work with a clinician who can match the treatment to your medical history, your goals, and your budget. The era of single-drug-fits-all obesity treatment is ending.